SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Nectar Lifesciences - Quaterly Results

13 Aug 2022 Evaluate
The company's total revenue for the quarter ended June 2022 saw a slight change in the total revenue, having registered a total revenue of Rs. 4030.23 millions.Profit for the quarter ended June 2022 rises by 90.24% to Rs. 39.36  millions from Rs. 20.69 millions.OP of the company witnessed a marginal growth to 422.09 millions from 407.87 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 4030.23 3844.53 4.83 4030.23 3844.53 4.83 16682.56 15428.96 8.12
Other Income 3.64 51.46 -92.93 3.64 51.46 -92.93 112.93 27.22 314.88
PBIDT 422.09 407.87 3.49 422.09 407.87 3.49 1701.31 1129.49 50.63
Interest 213.66 257.45 -17.01 213.66 257.45 -17.01 788.10 1120.32 -29.65
PBDT 208.43 150.42 38.57 208.43 150.42 38.57 913.21 -243.98 -474.30
Depreciation 146.95 142.78 2.92 146.95 142.78 2.92 569.68 602.53 -5.45
PBT 61.48 7.64 704.71 61.48 7.64 704.71 343.53 -846.51 -140.58
TAX 22.12 -13.05 -269.50 22.12 -13.05 -269.50 90.34 -115.04 -178.53
Deferred Tax 22.12 -13.05 -269.50 22.12 -13.05 -269.50 90.34 -200.90 -144.97
PAT 39.36 20.69 90.24 39.36 20.69 90.24 253.19 -731.47 -134.61
Equity 224.26 224.26 0.00 224.26 224.26 0.00 224.26 224.26 0.00
PBIDTM(%) 9.06 9.18 -1.28 10.47 10.61 -1.28 8.84 6.41 37.98

Nectar Lifesciences Share Price

12.26 0.32 (2.68%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×